<DOC>
	<DOCNO>NCT02230592</DOCNO>
	<brief_summary>Objective : Metabotropic glutamate receptor ( mGluRs ) G-protein coupled receptor respond glutamate activating protein inside nerve cell affect cell metabolism , thereby fine-tuning signal send cell maintain balance neuronal activity . mGluR subtype 1 ( mGluR1s ) locate several brain region , include cerebellum , hippocampus , olfactory bulb , basal ganglion . mGluR1 activation stimulate phospholipase C , result phosphoinositide hydrolysis increase intracellular calcium level . Successful development positron emission tomography ( PET ) ligand image mGlurR1 would impact clinical management brain disorder characterize disruption glutamatergic transmission , include anxiety stress disorder , drug addiction , epilepsy , Huntington disease , Parkinson disease . However , detailed study mGluR1s heretofore hinder lack high affinity selective ligand receptor subtype . The present protocol evaluate ability new PET ligand , [ 18F ] FIMX , image quantify mGluR1 brain healthy human volunteer . This protocol cover four phase : 1 . Phase 0 : screening whole-body scan ; 2 . Phase 1 : kinetic brain image quantify mGluR1 brain relative concurrent measurement parent radioligand arterial plasma ; 3 . Phase 2 : tracer successful Phase 1 , estimate radiation-absorbed dos [ 18F ] FIMX perform whole body imaging ; 4 . Phase 3 : test-retest analysis brain bind relative concurrent measurement parent radioligand arterial plasma . Study Population : Healthy adult female male volunteer ( n=22 , age 18 55 ) undergo brain whole-body imaging.. Design : This study begin screen whole-body scan confirm radioactivity fairly broad distribution several organ . For absolute quantification mGluR1 , 22 healthy control brain PET image use [ 18F ] FIMX arterial line . Up 12 test-retest scan . Eight additional subject whole body PET scan dosimetry , require arterial line . &lt; TAB &gt; Outcome Measures To assess absolute quantitation mGluR1 [ 18F ] FIMX , primarily use two outcome measure : identifiability time stability distribution volume calculate compartmental modeling . In test-retest study , calculate retest variability . To assess whole-body biodistribution dosimetry [ 18F ] FIMX use organ time-activity curve .</brief_summary>
	<brief_title>PET Imaging Brain mGluR1 Receptors Using 18FFIMX</brief_title>
	<detailed_description>Objective : Metabotropic glutamate receptor ( mGluRs ) G-protein coupled receptor respond glutamate activating protein inside nerve cell affect cell metabolism , thereby fine-tuning signal send cell maintain balance neuronal activity . mGluR subtype 1 ( mGluR1s ) locate several brain region , include cerebellum , hippocampus , olfactory bulb , basal ganglion . mGluR1 activation stimulate phospholipase C , result phosphoinositide hydrolysis increase intracellular calcium level . Successful development positron emission tomography ( PET ) ligand image mGlurR1 would impact clinical management brain disorder characterize disruption glutamatergic transmission , include anxiety stress disorder , drug addiction , epilepsy , Huntington disease , Parkinson disease . However , detailed study mGluR1s heretofore hinder lack high affinity selective ligand receptor subtype . The present protocol evaluate ability new PET ligand , [ 18F ] FIMX , image quantify mGluR1 brain healthy human volunteer . This protocol cover four phase : 1 . Phase 0 : screening whole-body scan ; 2 . Phase 1 : kinetic brain image quantify mGluR1 brain relative concurrent measurement parent radioligand arterial plasma ; 3 . Phase 2 : tracer successful Phase 1 , estimate radiation-absorbed dos [ 18F ] FIMX perform whole body imaging ; 4 . Phase 3 : test-retest analysis brain bind relative concurrent measurement parent radioligand arterial plasma . Study Population : Healthy adult female male volunteer ( n=22 , age 18 55 ) undergo brain whole-body imaging . Design : This study begin screen whole-body scan confirm radioactivity fairly broad distribution several organ . For absolute quantification mGluR1 , 22 healthy control brain PET image use [ 18F ] FIMX arterial line . Up 12 test-retest scan . Eight additional subject whole body PET scan dosimetry , require arterial line . &lt; TAB &gt; Outcome Measures To assess absolute quantitation mGluR1 [ 18F ] FIMX , primarily use two outcome measure : identifiability time stability distribution volume calculate compartmental modeling . In test-retest study , calculate retest variability . To assess whole-body biodistribution dosimetry [ 18F ] FIMX use organ time-activity curve .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>INCLUSION CRITERIA : Age 18 55 . Able give write informed consent . EXCLUSION CRITERIA : Any current Axis I diagnosis . Clinically significant laboratory abnormality . Positive HIV test . Unable MRI scan . History neurologic illness injury potential affect study data interpretation . Recent exposure radiation ( i.e . PET research ) , combine study , would allowable limit . Inability lie flat camera bed least two hour . Pregnancy breast feed . Able get pregnant use birth control . History drug alcohol abuse within 6 month history alcohol drug dependence ( except nicotine ) within 3 year Exclusion criterion dosimetry subject report , exception MRI contraindication , MRI perform subject .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 18, 2016</verification_date>
	<keyword>PET</keyword>
	<keyword>Metabolic Glutamate Receptors</keyword>
	<keyword>Brain Imaging</keyword>
</DOC>